Bone development in neurofibromatosis 1

Medical Hypotheses

Volumn 60, Issue 4, 2003, Pages 459-462

  Abdel Wanis, Mohamed E ^a   Kawahara, N ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; CORE BINDING FACTOR; GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN; NEUROFIBROMIN; PROTEIN P21; RAS PROTEIN;

ARTICLE; BONE DEVELOPMENT; CELL DAMAGE; COLLAGEN DEFECT; COLLAGEN SYNTHESIS; FIBROUS DYSPLASIA; GENETIC CODE; HUMAN; HYPOTHESIS; MITOGENESIS; NEUROFIBROMATOSIS; NONHUMAN; OLIGODENDROGLIA; ONCOGENE C FOS; OSTEOBLAST; PERIOSTEUM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTO ONCOGENE; PSEUDARTHROSIS; SKELETON MALFORMATION; SKIN FIBROBLAST;

EID: 0037375520     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00225-6     Document Type: Article

References (24)

1. Brannan C. I., Perkins A. S., Vogel K. S. et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994; 8: 1019-1029.
2. Crawford A. H. Pitfalls of spinal deformities associated with neurofibromatosis in children. Clin Orthop 1989; 245: 29-42.
3. Joseph K. N., Bowen J. R., MacEwen G. D. Unusual orthopedic manifestations of neurofibromatosis. Clin Orthop 1992; 278: 17-28.
4. Kim H. W., Weinstein S. T. The management of scoliosis in neurofibromatosis. Spine 1997; 22: 2770-2776.
5. Abdel-Wanis M. E., Kawahara N. Aetiology of spinal deformities in neurofibromatosis 1: new hypotheses. Med Hypotheses 2001; 56: 400-404, doi: 10.1054/mehy.2000. 1232.
6. Abdel-Wanis M. E., Kawahara N., Tomita K. The association of neurofibromatosis 1 and spinal deformity with primary hyperparathyroidism and osteomalacia: Might melatonin have a role?. J Orthop Sci 2001; 6: 194-199.
7. Lee L., Yan Y. H., Pharoah M. J. Radiographic features of the mandible in neurofibromatosis: a report of 10 cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81: 361-367.
8. von-Deimling A., Krone W., Menon A. G. Neurofibromatosis type 1: pathology, clinical features and molecular genetics. Brain Pathol 1995; 5: 153-162.
9. Hefti F., Bollini G., Dungl P. et al. Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data. J Pediatr Orthop B 2000; 9: 11-15.
10. Stocker K. M., Baizer L., Coston T., Sherman L., Ciment G. Regulated expression of neurofibromin in migrating neural crest cells of avian embryos. J Neurobiol 1995; 27: 535-552.
11. Yla-Outinen H., Aaltonen V., Bjorkstrand A. S. et al. Upregulation of tumor suppressor protein neurofibromin in normal human wound healing and in vitro evidence for platelet derived growth factor (PDGF) and transforming growth factor-beta1 (TGF-beta1) elicited increase in neurofibromin mRNA steady-state levels in dermal fibroblasts. J Invest Dermatol 1998; 110: 232-237.
12. Atit R. P., Crowe M. J., Greenhalgh D. G., Wenstrup R. J., Ratner N. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 1999; 112: 835-842.
13. Ducy P., Schinke T., Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-1504.
14. Candeliere G. A., Glorieux F. H., Prud'homme J., St.-Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 1995; 332: 1546-1551.
15. Grigoriadis A. E., Wang Z. Q., Wagner E. F. Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet 1995; 11: 436-441.
16. Mandrioli S., Carinci F., Dallera V., Calura G. Fibrous dysplasia. The clinico-therapeutic picture and new data on its etiology. A review of the literature. Minerva Stomatol 1998; 47: 37-44.
17. Khan S. N., Bostrom M. P. G., Lane J. M. Bone growth factors. Orthop Clin North Am 2000; 31: 375-387.
18. Habib A. A., Gulcher J. R., Hognason T., Zheng L., Stefansson K. The OMgp gene, a second growth suppressor within the NF1 gene. Oncogene 1998; 16: 1525-1531.
19. Grand R. J. A., Owen D. Review article. The biochemistry of ras p21. Biochem J 1991; 279: 609-631.
20. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270: 16483-16486.
21. Canalis E. Effect of growth factors on bone cell replication and differentiation. Clin Orthop 1985; 193: 246-263.
22. Fleming J. E., Jr., Cornell C. N., Muschler G. E. Bone cells and matrices in orthopedic tissue engineering. Orthop Clin North Am 2000; 31: 357-374.
23. Xiao G., Jiang D., Thomas P. et al. MAPK pathways activate and phosphrylate the osteoblast-specific transcription factor, Cbfa 1. J Biol Chem 2000; 275: 4453-4459.
24. Lau N., Feldkamp M. M., Roncari L. et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3/AKT signaling in neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59: 759-767.